Market reaction on the FTSE 100 was swift, marking AstraZeneca as the index’s biggest loser. Shareholders and analysts argue that Britain’s largest drugmaker possesses a robust internal pipeline and innovation profile that renders large-scale financial engineering unnecessary. Markus Manns, a portfolio manager at Union Investment, explicitly warned that the deal lacks both strategic and financial logic, noting that historical mega-mergers in the sector have frequently eroded shareholder value rather than creating it.

Concerns center on CEO Pascal Soriot’s long-standing strategy, which has favored research and development over the aggressive cost-cutting measures typical of massive corporate integration. Analysts at Jefferies echoed this sentiment, describing the company as a poor candidate for a transformation that could disrupt its current operational momentum. While AstraZeneca recently expanded its presence in the U.S. through a direct listing on the New York Stock Exchange, observers suggest that absorbing a major American pharmaceutical champion would introduce unwanted complexity to a well-run organization.